All AbMole products are for research use only, cannot be used for human consumption.
AT-56 is an orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS) (Ki = 75 μM, IC50 = 95 μM). AT-56 Inhibits the production of PGD2 from PGH2 in vitro, with no effect on PGE2 or PGF2α production. AT-56 inhibited human and mouse L-PGDSs in a concentration (3-250 microm)-dependent manner. AT-56 inhibits the L-PGDS activity in a competitive manner against the substrate PGH(2) (K(m) = 14 microm) with a K(i) value of 75 microm. AT-56 did not inhibit the binding of 13-cis-retinoic acid,which is a nonsubstrate lipophilic ligand, to L-PGDS.
 |
Source | BMC Gastroenterol (2015). Figure 7. AT-56 |
| Method | inflammatory | |
| Cell Lines | Primary culture of the rat ENS | |
| Concentrations | 95 μM | |
| Incubation Time | 24 h | |
| Results | LPS was used to induce an inflammatory stress. We showed that 1/ the ENS produced PGD2 in response to LPS, and 2/ at the IC50 concentration (95 μM) AT-56 reduced PGD2 production in response to LPS |
| Molecular Weight | 397.52 |
| Formula | C25H27N5 |
| CAS Number | 162640-98-4 |
| Solubility (25°C) | DMSO 10 mM |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Products |
|---|
| Diethylenetriaminepentaacetic dianhydride
Diethylenetriaminepentaacetic dianhydride (DTPA anhydride) is a bifunctional chelator whose anhydride can react with amino groups in proteins (such as lysine residues) to form stable amide bonds. Diethylenetriaminepentaacetic dianhydride (DTPA anhydride) can also bind to radionuclides to synthesize radionuclide-labeled drug conjugates (RDCs). |
| 3-Phenylthiophene
3-Phenylthiophene is a biochemical material that can be used in scientific research. 3-Phenylthiophene is a conducting polymer precursor. |
| DSPE-PEG-FA
DSPE-PEG2K-FA is a PEG derivative containing folic acid. DSPE-PEG2K-FA has a targeting effect and can bind to folic acid receptors in cancer cells. DSPE-PEG2K-FA forms micelles/lipid bilayers and can be used in research on targeted drug delivery systems. |
| Lifastuzumab
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. |
| GPVI antagonist 1
GPVI antagonist 1 is a glycoprotein VI (GPVI) platelet receptor antagonist. GPVI antagonist 1 inhibits collagen-induced platelet aggregation with an IC50 of 25.3 μM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
